Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference BioSpace
Whitehawk Therapeutics reports Q2 2026 net loss $16.6M; cash $190.0M funds into 2H 2028 TradingView
Opal Therapeutics Secures $1.25M NSF SBIR Phase II Award to Accelerate Women’s Health Drug Discovery Business Wire
Opal Therapeutics Secures $1.25M NSF SBIR Phase II Award to Accelerate Women’s Health Drug Discovery businesswire.com
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates BioSpace
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates FinancialContent
Transcriptome-based drug repurposing can accelerate therapeutic discovery, but is limited by fragmented resources, inconsistent quality control, and reliance on single perturbation databases. We developed CDRPipe ( C omputational D rug …
Infertility represents a significant global health burden, necessitating advanced therapeutic interventions. While Assisted Reproductive Technologies have revolutionized fertility treatment, they remain constrained by limited efficacy, off-target toxicity, and procedural complexity. …
Endometriosis is a chronic inflammatory disease characterised by ectopic endometrial tissue, progressive fibrosis and chronic pain, with a pathogenesis that goes beyond oestrogen dependence. The central question this review seeks …
Endometriosis is a debilitating chronic inflammatory disorder driven by extensive molecular reprogramming. Despite significant bench research into its pathogenesis, translating these molecular discoveries into clinical practices that improve patient outcomes …